Skip to content

Treatment of sudden idiopathic deafness with hyperbaric oxygen-therapy and intramuscular injection of CDP-choline. - Therapy of sudden deafness with CDP-choline and hyperbaric oxygen-therapy

Treatment of sudden idiopathic deafness with hyperbaric oxygen-therapy and intramuscular injection of CDP-choline. - Therapy of sudden deafness with CDP-choline and hyperbaric oxygen-therapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-011556-22-IT
Enrollment
50
Registered
2010-03-11
Start date
2009-05-07
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NONE MedDRA version: 9.1 Level: SOC Classification code 10013993

Interventions

Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: PSICCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Concentration unit: mg milligram(s) Concentration type: equal Co

Sponsors

FONDAZIONE IRCCS OSPEDALE MAGGIORE POLICLINICO MANGIAGALLI E REGINA ELENA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: o diagnosis and start of the treatment within 72 hours from onset of the symptoms o age>18 years o patients without severe systemic disease Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: o onset of the symptoms more than 72 hours o age<18 years o claustrophobia o psychosis o acute otitis o pregnancy (first-quarter) o hypertension without therapy o epilepsy o ischemic or congestive cardiac failure o severe pulmonary disease o glaucoma o detachment of the retina o pneumothorax or emphysema o tubaric dysfunction

Design outcomes

Primary

MeasureTime frame
Main Objective: Evaluation the number of patients that have: oa full retrieval of hearing (return to previous or to normal auditory threshold) after the therapy oan improvement of auditory threshold (>50%) after the therapy oa failure of the therapy (<50%);Secondary Objective: None;Primary end point(s): Healing of the patients

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026